Quantinno Capital Management LP Sells 38,572 Shares of Quest Diagnostics Incorporated $DGX

Quantinno Capital Management LP decreased its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 14.3% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 231,025 shares of the medical research company’s stock after selling 38,572 shares during the period. Quantinno Capital Management LP’s holdings in Quest Diagnostics were worth $45,276,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Key Financial Inc grew its holdings in Quest Diagnostics by 1,728.6% during the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock valued at $25,000 after buying an additional 121 shares in the last quarter. Quattro Advisors LLC purchased a new stake in shares of Quest Diagnostics in the fourth quarter worth about $25,000. DV Equities LLC bought a new position in shares of Quest Diagnostics in the fourth quarter valued at approximately $27,000. Sittner & Nelson LLC bought a new position in shares of Quest Diagnostics in the fourth quarter valued at approximately $29,000. Finally, McIlrath & Eck LLC purchased a new position in Quest Diagnostics during the fourth quarter valued at approximately $32,000. Institutional investors own 88.06% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on DGX. Truist Financial raised their price target on shares of Quest Diagnostics from $225.00 to $250.00 and gave the company a “hold” rating in a report on Friday, July 24th. Barclays increased their price objective on Quest Diagnostics from $230.00 to $250.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Robert W. Baird lifted their price objective on Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Argus set a $260.00 target price on Quest Diagnostics in a research report on Wednesday. Finally, Wall Street Zen upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday. Six equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $235.31.

Insiders Place Their Bets

In other news, SVP Karthik Kuppusamy sold 8,147 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the transaction, the senior vice president directly owned 13,510 shares in the company, valued at approximately $2,702,000. This represents a 37.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $194.14, for a total value of $1,941,400.00. Following the transaction, the chief executive officer owned 132,423 shares in the company, valued at $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 19,747 shares of company stock valued at $3,947,088 over the last 90 days. Insiders own 0.88% of the company’s stock.

Quest Diagnostics Price Performance

DGX stock opened at $235.01 on Thursday. The firm has a 50 day simple moving average of $205.78 and a two-hundred day simple moving average of $198.92. The stock has a market cap of $25.94 billion, a PE ratio of 24.95, a P/E/G ratio of 2.17 and a beta of 0.58. Quest Diagnostics Incorporated has a one year low of $166.75 and a one year high of $240.13. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The firm had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $2.97 billion. During the same quarter last year, the company posted $2.62 EPS. The business’s quarterly revenue was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, analysts predict that Quest Diagnostics Incorporated will post 11.16 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 22nd. Shareholders of record on Wednesday, July 8th were given a dividend of $0.86 per share. The ex-dividend date was Wednesday, July 8th. This represents a $3.44 dividend on an annualized basis and a yield of 1.5%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 36.52%.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.